Lentivirus vector plasmid of human MYC driven by Tet-responsive promoter and hKO1-2A-rtTA driven by CMV promoter.
Clone info. | Lentivirus vector plasmid of human MYC driven by Tet-responsive promoter and hKO1-2A-rtTA driven by CMV promoter. |
---|---|
Comment | Commonly requested with pCMV-VSV-G-RSV-Rev (RDB04393) and pCAG-HIVgp (RDB04394). |
Vector backbone | CSIV-TRE-RfA-CMV-KT (RDB12923) (Plasmid) |
Selectable markers | Ampicillin (E. coli). Please note that Zeo resistance marker is not included in the lentivirus produced from this vector. |
Gene/insert name | Human MYC cDNA |
Depositor|Developer | Miyoshi, Hiroyuki | |
Sequence | RDB12923z.seq | Remarks, protocol and/or map (pdf) | RDB12923.pdf |
---|
Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms | Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ] MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ] Please visit Ordering instruction.[link] |
---|---|
Terms and conditions for distribution | The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit academic purpose. The RECIPIENT agrees to expressly describe the late Dr. Hiroyuki Miyoshi as the Developer. |
Remarks | ((Remarks)) Remember that you will be working with samples containing infectious virus. Please contact us. We will provide you with appropriate documents. Gateway® Expression clone. Please refer Life Technologies Corporation signs license agreement with RIKEN BRC. |
必要書類 | 提供依頼書 [依頼書の記入例 ] 提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ] 遺伝子組換え生物の受入れ確認書が必要です。当室にご請求ください。 手続きの概要は、「レンチウイルスベクターの提供申し込み」をご覧ください。 |
---|---|
MTAに書く使用条件 | 本件研究材料は、非営利機関の非営利学術研究に限って提供する。本件研究材料を利用した研究結果等を発表する際は、本件研究材料が故三好浩之博士により開発されたことを明示する。 |
備考 | 【使用上の注意】このリソースはウイルス粒子産生用のため、取扱いに注意が必要です。 Gateway®テクノロジーを用いた発現クローンです。「Gateway®テクノロジーを用いたクローンの提供と寄託のご案内」をご覧ください。 |
Catalog # | Resource name | Availability | Shipping form | Fee (non-profit org.) |
---|---|---|---|---|
RDB12923 | CSIV-TRE-hc-Myc-CMV-KT | Under QC test. Please contact us. | DNA solution |
Materials & Methods section:
The CSIV-TRE-hc-Myc-CMV-KT was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB12923). |
Reference section:
Tai, M.C., Kajino, T., Nakatochi, M., Arima, C., Shimada, Y., Suzuki, M., Miyoshi, H., Yatabe, Y., Yanagisawa, K., Takahashi, T., miR-342-3p regulates MYC transcriptional activity via direct repression of E2F1 in human lung cancer. Carcinogenesis 36 (12): 1464-1473 (2015). PMID 26483346. [link to RRC of NBRP] |
Further references such as user reports and related articles (go to bottom)
Please wait for results of QC test to be uploaded. This clone will be sequenced a portion for examination.
Original, user report and related articles
original | Tai, M.C., miR-342-3p regulates MYC transcriptional activity via direct repression of E2F1 in human lung cancer. Carcinogenesis 36 (12): 1464-1473 (2015). PMID 26483346. [link to RRC of NBRP] |
---|
Featured content